Two of Europe’s biggest drugmakers said they’re looking at ways to protect themselves from US President Donald Trump’s potential tariffs.

Swiss and French pharmaceutical companies Novartis and Sanofi argue that the EU should adjust its drug prices to better align with those in the US.

Sanofi has been forging ever-closer ties with its mRNA partner Translate Bio since the two started working together in 2018, and has now gone all in, offering $3.2 billion to buy the company outright.

Sanofi is scheduled to report results for the first quarter on Thursday. Here is what you need to know. BUSINESS OPERATING PROFIT FORECAST: The French pharmaceutical company is expected to make 2. ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder. It’s ...

Sanofi plans a phase 3 amlitelimab trial; safety remained consistent over 60 weeks of treatment. China’s new tariffs just reignited the same market patterns that led to triple- and quadruple ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...

April 18 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a ...